Navigation Links
Shire to Initiate Two Phase 4 Clinical Trials to Compare Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta® (methylphenidate HCl) Extended-Release Tablets, (CII)
Date:3/6/2012

sdexamfetamine dimesylate)

Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children ages 6 to 12 years, approved in April 2008 to treat ADHD in adults, and approved in November 2010 to treat ADHD in adolescents ages 13 to 17, is currently available in six once-daily dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.

Additional information about Vyvanse is available at http://www.vyvanse.com.

INDICATION

Vyvanse is indicated for the treatment of ADHD in patients ages 6 and above as part of a total treatment plan that may include other measures (psychological, educational, social). Efficacy was established in short-term controlled studies in children aged 6 to 17 and adults. Vyvanse is also approved as a maintenance treatment for adults with ADHD based on one randomized withdrawal study. Extended use of Vyvanse should be periodically reevaluated to determine its long-term usefulness for the individual patient.

IMPORTANT SAFETY INFORMATION

WARNING: POTENTIAL FOR MISUSE, ABUSE, ADDICTION, AND DIVERSION

See Full Prescribing Information for complete Boxed WARNING.

• Vyvanse is a Schedule II controlled substance. Stimulants, such as amphetamines and methylphenidates, are subject to misuse, abuse, addiction, and criminal diversion.

• Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.

Contraindications: Known hypersensitivity to amphetamines or other ingredients in Vyvanse.

Anaphylactic reactions, Stevens-Johnson Syndrome, angioedema, and urticaria have been observed in postmarketing reports. Using Vyvanse with monoamine oxidase inhibitors (MAOIs) can result in hypertensive crisis. Stop MAOIs at least 14 days prior to Vyvanse use.

Sudden death, stroke and myocardial infarction have
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... PLAINFIELD, N.J., Feb. 17, 2011 Dr. Abraham Abuchowski, ... by the U.S. Small Business Administration on February 15 ... and job creation. Dr. Abuchowski was one of eight ... industry. Dr. Abuchowski was the originator ...
... Symmetry Medical Inc. (NYSE: SMA ), a ... industry and other medical markets, announced today preliminary unaudited revenue ... Symmetry anticipates full year 2010 revenue of approximately $361 ... $364 million. For the full year 2011, ...
Cached Medicine Technology:Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration 2Symmetry Medical Announces Preliminary Unaudited Full Year 2010 Revenue 2Symmetry Medical Announces Preliminary Unaudited Full Year 2010 Revenue 3
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Though most patients ... medication and therapy, between 10 percent to 20 percent ... to standard care, experts say. However, patients with ... form of a type of brain surgery that disables ... The challenge: to distinguish between patients most likely to ...
(Date:12/24/2014)... you are a high-risk heart patient, you might be ... cardiologist, new research suggests. Survival rates among these ... professional meetings, Harvard researchers report. Sixty percent of ... teaching hospital during one of these meetings died within ... were not taking place. "That,s a tremendous reduction ...
(Date:12/22/2014)... December 22, 2014 As part ... senior care service in San Diego and ... of its senior care team with ongoing online ... Golden Care is provided by Caregiverlist®. Caregiverlist® ... caregivers with the most reliable eldercare options, highest ...
(Date:12/22/2014)... Los Angeles, CA (PRWEB) December 22, 2014 ... the names have changed. The reason why most fad ... work - temporarily. The problem with fad diets is that, ... loss tapers, leaving the dieter uncertain of how to reset ... mode. For this reason, Diet Doc developed their all-inclusive ...
Breaking Medicine News(10 mins):Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... Minyard Food Stores Inc. is offering any,expectant mom ... Life Healthy(TM)" initiative, the company announced,today., Just in ... will,offer free prenatal vitamins to all expectant mothers for ... any Carnival, Minyard or,Sack,n Save store in North Texas. ...
... and other hospital and healthcare advocates from across the,state ... protest the nearly $300,million in healthcare cuts proposed in ... Gone Tomorrow," a Rally to Preserve Our Healthcare, ... WHEN: 12 noon, May 12, The "Care Today, ...
... Consumer,Healthcare, marketer of the leading smoking cessation products ... applauds,the release of the updated 2008 U.S. Public ... Dependence. Too many smokers lower their,chances of quitting ... The Guideline is an important validation of the ...
... Vaccinogen Inc. said Dutch health,authorities licensed it to manufacture ... to more than $100 million of,potential European sales., ... Emmen, The,Netherlands also paves the way to its pivotal ... before the vaccine can be sold in the United,States., ...
... 7 Hamline University School of Law,s,Health Law Institute ... offer a Health Care Corporate Compliance Certificate,education program. Hamline,s ... the Upper Midwest and one of only four programs ... program is designed to be completed within,one year, with ...
... studies indicate improved IVF procedures may spare patients money & ... ... Calif., May 7 Spurred by recent research,California fertility specialists are ... -- saying newer,and improving in vitro fertilization (IVF) technology tends to ...
Cached Medicine News:Health News:Expectant Moms Offered Free Prenatal Prescription Vitamins at D-FW Area Carnival, Minyard and Sack'n Save Stores 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 3Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:Fertility Doctors: Studies Suggest Artificial Insemination Increasingly Second Choice 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: